Form 4: Selvakesari Anand reports acquisition/exercise transactions in C
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Selvakesari Anand reported acquisition or exercise transactions in a Form 4 filing for C. The filing lists transactions totaling 29,202 shares. Following the reported transactions, holdings were 231,227 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Selvakesari Anand
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 29,202.1 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 231,227.31 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Citigroup (C) report for COO Selvakesari Anand?
Citigroup’s Chief Operating Officer Selvakesari Anand reported receiving an award of 29,202.1 shares of common stock. The grant was made at $0.00 per share as deferred stock under Citigroup’s 2019 Stock Incentive Plan, increasing his direct beneficial ownership to 231,227.31 shares.
Is the new Citigroup (C) stock award to the COO immediately saleable?
No, none of the awarded 29,202.1 Citigroup shares are eligible for immediate sale. The grant is deferred stock that vests over time, limiting near-term liquidity and aligning the Chief Operating Officer’s compensation more closely with Citigroup’s longer-term share performance and retention goals.
How does the Citigroup (C) deferred stock award to the COO vest?
The 29,202.1-share deferred stock award vests in four equal annual installments. Vesting begins on January 20, 2027, with one-quarter of the award vesting each year thereafter, creating a multi‑year incentive structure tied to continued service and Citigroup’s ongoing performance.
Under which plan was the Citigroup (C) COO’s deferred stock award granted?
The 29,202.1-share award was granted under Citigroup’s 2019 Stock Incentive Plan. This plan provides equity-based compensation, and in this case the grant is structured as deferred stock, with four equal annual vesting installments beginning January 20, 2027, and no immediate sale permitted.